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Background: Type-2 diabetes mellitus has a major impact on health related quality of life (HRQoL). We aimed to
identify patient and treatment related variables having a major impact.
Methods: DiaRegis is a prospective diabetes registry. The EQ-5D was used to describe differences in HRQoL at
baseline. Odds ratios (OR) with 95% confidence intervals (CI) were determined from univariable regression analysis.
For the identification of independent predictors of a low score on the EQ-5D, multivariable unconditional logistic
regression analysis was performed.
Results: A total of 2,760 patients were available for the present analysis (46.7% female, median age 66.2 years). Patients
had considerable co-morbidity (18.3% coronary artery disease, 10.6% heart failure, 5.9% PAD and 5.0% stroke/TIA). Baseline
HbA1c was 7.4%, fasting- and postprandial plasma glucose 139 mg/dl and 183 mg/dl.
The median EQ-5D was 0.9 (interquartile range [IQR] 0.8–1.0). Independent predictors for a low EQ-5D were age > 66 years
(OR 1.49; 95%CI 1.08–2.06), female gender (2.11; 1.55–2.86), hypertension (1.73; 1.03–2.93), peripheral neuropathy (1.62; 0.93–
2.84) and clinically relevant depression (11.01; 3.97–30.50). There was no influence of dysglycaemia on the EQ-5D score.
Conclusion: The present study suggests, that co-morbidity but not average glycaemic control reduces health related
quality of life in type 2 diabetes mellitus.Introduction
In the treatment of type-2 diabetes there is a strong focus
to achieve glycaemic control and to prevent directly quan-
tifiable disease related micro- and macrovascular compli-
cations. The achievement of these goals is perceived to be
an indicator of a good quality of care. However, this re-
flects disease control rather than a patient’s health related
quality of life (HRQoL) [1] and patients’ perceived HRQoL
does not necessarily match patients’ ratings [2].
There are a number of studies showing that HRQoL is
reduced in type-2 diabetic patients compared to the gen-
eral population [3] and also somewhat lower than in pa-
tients with other chronic disease entities [4]. However,* Correspondence: peter.bramlage@ippmed.de
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reproduction in any medium, provided the orthe relationship between glycaemic control and HRQoL
of patients with type 2 diabetes is unclear. It has been
suggested that reducing glucose to normal levels may
enhance well-being, particularly as fatigue is frequent in
patients with elevated blood glucose levels [5]. But while
some studies have shown that improved HbA1c is associ-
ated with short-term improvement in HRQoL [6], others
were not able to confirm this [7]. Further antidiabetic
treatment such as sulfonylureas might impact HRQoL be-
cause of a potentially increased body weight and the risk
of hypoglycaemia [8,9]. More recent drug developments
such as DDP-4 inhibitors on the other hand rather de-
crease body weight and patients have a low propensity for
hypoglycaemia which might have a positive impact on
HRQoL. The most consistent impact on HRQoL has been
reported for co-morbidities [10-13] and disease-relatedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ample, microvascular complications, heart failure and de-
pression were most strongly related to decreased HRQoL,
independently of the duration of diabetes while patients
without symptomatic co-morbidities did not have a signifi-
cantly reduced HRQoL [10]. In agreement with this, symp-
tomatic co-morbidities such as osteoarthritis and neuropathic
pain have a stronger impact on HRQoL than largely asymp-
tomatic co-morbidities such as hypertension [12].
Given the vast but partially conflicting evidence on
HRQoL from a number of different cohorts and research
settings we used the DiaRegis dataset consisting of a large
cohort of type-2 diabetic patients on oral antidiabetic
pharmacotherapy [15] to identify independent patient and
treatment related variables that affect HRQoL.
Methods
DiaRegis is a prospective, observational, German, multi-
center registry. It is conducted in accordance with the
principles of Good Epidemiology Practice (GEP), and ap-
plicable regulatory requirements. The protocol of this
registry was approved by the ethics committee of the
Landesärztekammer Thüringen in Jena, Germany on
March 4th 2009 [15,16]. Patients being enrolled into this
registry provided written informed consent.
Patients
Between June 2009 and March 2010 patients with type-2
diabetes aged ≥ 40 years being on oral mono or dual com-
bination antidiabetic therapy (no injectables such as insu-
lin or GLP-1 analogs) were included in which the treating
physician intensified treatment at baseline. Intensification
was achieved by either increasing the dose of originally
prescribed drugs and/or by exchanging drugs or by adding
further drugs to the previously used ones. There was no
interaction with the physician to select particular patients
to be intensified, nor the direction of intensification pre-
defined. All eligible patients were enrolled on a consecu-
tive basis. Patients not under regular supervision of the
treating physician for the duration of the study, those with
type-1 diabetes, pregnancy, diabetes secondary to malnu-
trition, infection or surgery, with maturity onset diabetes
of the young, known cancer or limited life expectancy,
acute emergencies, participation in a clinical trial and pa-
tients with further reasons that made it impossible or
highly problematic for the patient to participate and come
to the follow-up visits were excluded.
Documentation
Patient characteristics at baseline were entered via a secure
website directly into an electronic database at the Stiftung
für Herzinfarktforschung, Ludwigshafen, Germany. At this
stage they were automatically checked for plausibility and
completeness. Data from the patient questionnaire (paperversion), which was asked to be completed by the patient
during the visit, were transferred to the responsible CRO.
The questionnaires were scanned, decoded and transferred
to the Institut für Herzinfarktforschung for evaluation.
The EQ-5D (EuroQol)
The EQ-5D [17,18] was used to evaluate health related
quality of life (HR-QoL) in an analysis of the DiaRegis
baseline population. The EQ-5D is one of the world wid-
est used standardised, validated generic instruments for
measuring HRQoL. It consists of a descriptive system
(part I) and a visual analogue scale (VAS) (part II). The
descriptive system comprises 5 dimensions (mobility,
self-care, usual activities, pain / discomfort, anxiety / de-
pression), each being classified as no problems (score 1),
some problems (score 2) or severe problems (score 3).
The EQ VAS records the respondent´s self rated health
on a vertical, visual analogue scale, where the endpoints
are labelled “Best imaginable” and “Worst imaginable”
health status. The EQ-5D score ranges from 0 to 1 and
can be calculated by applying scores from the EQ-5D
preference weights elicited from the general population.
For this study, the EQ-5D score was calculated using the
value set for the European population [17,18]. Further
investigations have demonstrated the usefulness of the
EQ-5D in identifying determinants of health states
[19,20]. The minimal important difference for the EQ-
5D has been reported in the relevant literature as a
change in score of at least 0.05 points [21].
Statistical analysis
The statistical analysis was performed using SAS, version 9.2
(Cary, North Carolina, U.S.A.). All descriptive statistics are
based on available cases. The distribution of metric variables
is described with medians and quartiles. The EQ-5D patient
data were analysed using the full model of the validated in-
strument for the German population [22]. Three tertiles were
built to create patient groups with worse, average and above
average QoL.Cochran-Armitage or Jonckheere-Terpstra tests
were used to describe differences across these tertiles. Odds
ratios (OR) with 95% confidence intervals were determined
from univariable regression analysis. For risk analyses with
HRQoL as outcome variable, multivariable unconditional lo-
gistic regression analysis was performed. Variables were se-
lected from univariable analysis and amended by variables
derived from clinical considerations. To facilitate interpret-
ation and presentation of data, continuous variables were cat-
egorized according to clinically relevant classes.
Results
Out of 3,810 patients overall, 2,760 patients had
complete data for the present analysis of which 1,288
(46.7%) were female (Table 1). Median age was 66.2
(interquartile range [IQR] 57.6–75.6) years and the BMI
Table 1 Patient characteristics and variables predictive for a reduced EQ-5D score based on univariable and
multivariable unconditional regression analysis




OR (95%CI) OR (95%CI)
Age (years) 66.2 (57.6–73.0) > 66 vs. ≤ 66 years 1.77 (1.47–2.13) 1.49 (1.08–2.06)
Female gender 46.7 female vs. male 1.86 (1.86–2.24) 2.11 (1.55–2.86)
BMI > 30 kg/m2 49.3 > 30 vs. ≤ 30 kg/m2 1.40 (1.16–1.68) 1.24 (0.91–1.69)
Blood glucose
HbA1c (%) 7.4 (6.8–8.2) > 7.4 vs. ≤ 7.4% 0.97 (0.80.1.16) 0.91 (0.64–1.28)
Fasting plasma glucose (mg/dl) 139 (118–167) > 139 vs. ≤ 139 mg/dl 1.05 (0.86–1.28) 0.91 (0.64–1.29)
Postprandial plasma glucose (mg/dl) 183 (154–220) > 183 vs. ≤ 183 mg/dl 1.07 (0.84–1.37) 1.20 (0.85–1.71)
Antidiabetic Pharmacotherapy
Metformin 84.6 yes vs. no 0.81 (0.63–1.61) 0.94 (0.57–1.56)
Sulfonylureas 28.1 yes vs. no 1.13 (0.92–1.39) 1.14 (0.75–1.71)
Glucosidase inhibitors 2.2 yes vs. no 1.19 (0.61–2.29) 1.71 (0.56–5.18)
Glinides 4.0 yes vs. no 1.02 (0.63–1.66) 1.12 (0.50–2.52)
Thiazolidinediones 6.4 yes vs. no 0.93 (0.64–1.35) 1.60 (0.90–2.84)
DPP-4 inhibitors 5.0 yes vs. no 1.11 (0.73–1.7) 0.97 (0.46–2.04)
Co-morbidities
Hypertension 85.0 yes vs. no 1.83 (1.40–2.40) 1.62 (0.93–2.84)
CAD 18.3 yes vs. no 2.21 (1.73–2.80) 1.39 (0.83–2.31)
Peripheral neuropathy 13.7 yes vs. no 2.51 (1.91–3.3) 1.73 (1.03–2.93)
Heart failure 10.6 yes vs. no 2.01 (1.50–2.70) 1.14 (0.67–1.95)
PAD 5.9 yes vs. no 1.89 (1.28–2.82) 1.46 (0.76–2.81)
Clin. rel. depression 5.3 yes vs. no 10.16 (5.38–19.18) 11.01 (3.97–30.50)
Stroke/TIA 5.0 yes vs. no 1.98 (1.29–3.04) 1.37 (0.69–2.73)
Non-proliferative retinopathy 3.9 yes vs. no 1.76 (1.09–2.83) 1.08 (0.54–2.15)
Autonomous neuropathy 3.4 yes vs. no 2.72 (1.57–4.72) 1.34 (0.56–3.17)
Limb amputation 0.8 yes vs. no 2.38 (0.81–6.99) 0.64 (0.13–3.27)
≥ 2 co-morbidities* 68.2 yes vs. no 1.90 (1.55–2.33) 1.33 (0.77–2.29)
CV Pharmacotherapy
ARB 22.3 yes vs. no 1.16 (0.93–1.45) 1.20 (0.78–1.87)
ACE inhibitors 50.3 yes vs. no 1.34 (1.11–1.61) 1.08 (0.74–1.58)
Beta-Blocker 47.0 yes vs. no 1.58 (1.31–1.90) 0.88 (0.64–1.23)
CCB 26.2 yes vs. no 1.52 (1.23–1.88) 1.29 (0.92–1.81)
Diuretics 41.2 yes vs. no 1.60 (1.32–1.93) 1.09 (0.78–1.52)
Statins 41.7 yes vs. no 1.28 (1.06–1.54) 1.06 (0.77–1.46)
Anamn. Hypoglycaemia 11.7 yes vs. no 2.01 (1.51–2.66) 1.40 (0.88–2.22)
Legend: *co-morbidities considered are listed under “co-morbidities” in the table; IQR interquartile range; OR odds ratio; CI confidence interval; BMI body mass
index; DPP-4 dipeptidyl-peptidase 4 inhibitor; CAD coronary artery disease; PAD peripheral arterial disease; TIA transitory ischemic attack; CV cardiovascular; ARB
angiotensin receptor blocker; CCB calcium channel blocker.
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mined by the EQ-5D was 0.9 (IQR 0.8–1.0).
Impact of glycaemic control
Median HbA1c was 7.4 (IQR 6.8–8.2) in the total
cohort, which was not different between tertiles ofthe EQ-5D (p = 0.97). Likewise no relationship be-
tween fasting- (p = 0.80) or postprandial plasma glu-
cose (p = 0.16) and EQ-5D was observed (Table 1).
In multivariable regression analyses considering variables
depicted in Table 1, the OR was 0.91 (0.64–1.28) for the
HbA1c, 0.91 (0.64–1.29) for fasting- and 1.20 (0.85–1.71)
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impact.
Impact of hypoglycemia
Physicians reported that 11.7% of patients had suffered
from episodes of hypoglycaemia during the 12 months
prior to inclusion, which were more frequent in patients
with an EQ-5D score in the lowest tertile (16.7% vs. 9.1%
in the highest tertile; OR 2.01; 95%CI 1.51–2.66) (Figure 1).
After adjusting for age, gender and body mass index the
association with asymptomatic hypoglycaemia (OR 2.26;
95%CI 1.49–3.44) and symptomatic hypoglycaemia with-
out the need for help (1.76; 1.26–2.47) remained signifi-
cant, while symptomatic hypoglycaemia with the need for
help became significant (2.34; 1.01–5.43). A need for
hospitalization had a high OR assigned but confidence in-


















… is more frequent in the highest tertile
Hypoglyc
Figure 1 HRQoL in patients with hypoglycaemia. Legend: Odds Ratios
mass index.multivariable model depicted in Table 1 hypoglycaemia
lost its association with a reduced EQ-5D score.
Impact of antidiabetic pharmacotherapy
84.6% of patients received metformin, 28.1% sulfonyl-
ureas, 2.2% glucosidase inhibitors, 4.0% glinides, 6.4%
glitazones and 5.0% DPP-4 inhibitors (Table 1). Neither
of these compounds was associated with a reduced EQ-
5D score, which was confirmed in univariable and also
multivariable regression analyses. This also applied for
69.7% of patients receiving oral monotherapy and 30.3%
receiving any oral combination therapy.
Impact of co-morbidity and patient related variables on
the EQ-5D score
Patients had a considerable co-morbidity burden (Figure 2),
which was higher in patients with a low score on the10.00 100.00

















… is more frequent in the lowest tertile
aemia …
in the lower panel were adjusted for an age, gender and body









EQ-5D lowest tertile (<0.871)
EQ-5D middel tertile (0.872-0.992)
EQ-5D highest tertile (>0.993)
p<0.0001 for trend 
Figure 2 Co-morbidity burden and health related quality of life
(EQ-5D). Legend: co-morbidities considered were dyslipidemia,
hypertension, malignancy, coronary artery disease, stroke/transitory
ischemic attack (TIA), peripheral artery disease (PAD), heart failure,
neuropathy, retinopathy, dialysis, clinically relevant depression.
Table 2 EQ-5D items in patients per co-morbidity status




I have no problems in walking about 72.3 79.5
I have some problems in walking about 27.6 20.4
I am confined to bed 0.1 0.1
Self-Care
I have no problems with self-care 92.2 94.9
I have some problems washing or
dressing myself
7.4 4.7
I am unable to wash or dress myself 0.5 0.5
Usual Activities
I have no problems performing my
usual activities
80.8 86.7
I have some problems performing my
usual activities
17.9 12.3




I have no pain or discomfort 43.3 48.4
I have moderate pain or discomfort 50.1 46.3
I have extreme pain or discomfort 6.6 5.3
Anxiety/Depression
I am not anxious or depressed 72.6 76.1
I am moderately anxious or depressed 24.8 22.0
I am extremely anxious or depressed 2.6 2.0
EuroQoL EQ-5D visual analogue scale 70 (55–80) 73 (60–8
EQ-5D Score (Full Model) [0–1] 0.9 (0.8–1.0) 0.9 (0.9–1
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often female and had a higher median BMI and had cor-
onary artery disease, stroke/transitory ischemic attack
(TIA), peripheral artery disease (PAD), heart failure and
peripheral neuropathy more frequent (Table 1). After mul-
tivariable analysis hypertension (OR 1.62; 95%CI 0.93–
2.84), peripheral neuropathy (OR 1.73, 95%CI 1.03–2.93)
and clinically relevant depression (OR 11.01; 95%CI 3.97–
30.50) but not heart failure or coronary artery disease
(CAD) remained significant predictors. Table 2 lists the
items of the EQ-5D per co-morbidity status and reveals a
substantially altered response pattern which was present
troughout all domains, but particularly pronounced in pa-
tients with pain/discomfort.
Concomittant cardiovascular pharmacotherapy such as
ACE inhibitors, betablockers, calciumchannel blockers,
diuretics and statins were more frequent in patients with
a low EQ-5D score. They were however rather reflecting
the substantial co-morbidity of patients because all asso-
ciations became insignificant after multivariable analysis.idity
2 co-morbidities > 2 co-morbidities p-value

















0) 70 (53–80) 60 (50–70) <0.0001
.0) 0.9 (0.8–1.0) 0.9 (0.8–0.9) <0.0001
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Type-2 diabetes has been described to be associated with
a reduced health related quality of life [3,4]. Using the
EQ-5D questionnaire we found that this was mostly re-
lated to the presence of co-morbidity and episodes of
hypoglycaemia but not to average glycaemic control.
With a median score of 0.9 diabetic patients scored high
on the EQ-5D in general while there were only few pa-
tients with substantially lowered scores (<0.5). On the
other hand changes as little as 0.05 have been reported
as the minimal important difference for the EQ-5D [21],
illustrating that there are clinically relevant differences
in HRQoL between those in the lowest and highest
tertile of the EQ-5D range seen in DiaRegis.
Glycaemic control
We found no association between glycaemic control (de-
fined as HbA1c, fasting- or postprandial glucose levels)
and changes in the EQ-5D scoring, which remained ro-
bust even in multivariable analyses. While the findings are
in agreement with a number of other analyses [4,23,24],
they are in contrast to data reported by Testa et al., who
found that improved glycaemic control was associated
with substantial improvements in QoL [6]. Quality-of-life
treatment differences (SD units) for symptom distress
(+0.59; p < 0.001), general perceived health (+0.36;
p = 0.004), cognitive functioning (+0.34; p = 0.005),
and the overall visual analog scale (VAS) (+0.24; p = 0.04)
were significantly more favorable for active therapy. In that
study patients with established type-2 diabetes were washed
out from prior antidiabetic pharmacotherapy for 3 weeks
and then randomized to glipizide GITS or placebo for 12
weeks. HbA1c increased to 9.3% and fasting blood glucose
to 168 mg/dl in the placebo group while it was reduced to
7.5% and 126 mg/dl in the glipizide group. In another ana-
lysis by Klein et al. diabetic patients after 14 years of follow-
up were subjected to the Short Form 36 (SF-36), which
demonstrated an improved quality of life with low HbA1c
values [25], this was however not multivariable adjusted.
On this background the lack of an association between
glycaemic control and HRQoL in our study might be re-
lated to the fact that the group of patients was rather
homogenous, selected by restricting recruitment to those
with oral antidiabetic therapy, and showing a rather nar-
row range of HbA1c values (median 7.4; interquartile
range 6.8–8.2) that appeared to be stable over time.
Taken together this might suggest that average contem-
porary glycaemic control in a stable environment might
prevent detecting differences in QoL that may arise in
patients with extreme differences in glycaemic control.
Antidiabetic pharmacotherapy
Differences in HRQol with the selection of oral antidiabetic
pharmacotherapy are, on the background of a largelyabsent impact of glycaemic control, related to the side
effect profile which might include weight gain and/or
hypoglycaemia. In the analysis of our dataset which in-
cluded patients being largely treated with metformin
(84.6%) and/or sulfonylureas (28.1%) and also to a
lesser extent with other oral antidiabetic drugs, we
found no impact of antidiabetic pharmacotherapy in
univariable or multivariable regression analyses. This is
compatible with other analyses of observational regis-
tries and larger outcomes studies which also identified
no such association [4,26,27].
Hypoglycemia is a frequent treatment related compli-
cations that might be reduced by properly selecting
antidiabetic pharmacotherapy and considering specific
patient characteristics use [28,29]. There are only few reports
demonstrating that hypoglycaemia with oral antidiabetic
drugs might have an impact. Alvarez-Guisasola et al.
reported for example from a large observational, multi-
center, cross sectional study including 1,709 patients with
type-2 diabetes (mean age 63 years, 45% female, mean
HbA1c 7.1%, 38% hypoglycaemic symptoms within the
last 12 months), that QoL was substantially reduced with
hypoglycaemia [30]. This is well compatible with our own
observations. Patients received either sulfonylureas or
thiazolidinediones on top of metformin monotherapy.
Those reporting hypoglycaemic symptoms had signifi-
cantly lower EQ-5D VAS scores (mean difference −4.33,
p < 0.0001) in adjusted linear regression analyses. Relative
to those not reporting symptoms, the adjusted decrement
to quality of life increased with severity of hypoglycaemia
(mild: -2.68, p = 0.0039; moderate: -6.42, p < 0.0001; se-
vere: -16.09, p < 0.0001). They established no link however
between the choice of either sulfonylureas or glitazones
and the frequency of hypoglycaemia. Further research is
clearly needed to link antidiabetic treatment options to
hypoglycaemia and their impact on health related quality
of life. It is however plausible that the incidence rates of
(symptomatic) hypoglycaemia with single agents in our
cohort is not sufficient to establish such a link from a stat-
istical perspective.
Co-morbidity and patient related variables
Patients in our cohort had a substantial co-morbidity
which ranged however from none to more than 6 co-
morbidities. After multivariable analysis hypertension
(OR 1.62; 95%CI 0.93–2.84), peripheral neuropathy (OR
1.73, 95%CI 1.03–2.93) and clinically relevant depression
(OR 11.01; 95%CI 3.97–30.50) but not heart failure or
coronary artery disease (CAD) remained significant pre-
dictors. This is in partial agreement to previous findings
[10-14] that have repeatedly shown, that symptomatic
more than asymptomatic co-morbidities are responsible
for this observation. Miksch for example illustrated that
the impact of osteoarthritis as a disabling and painful
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largely asymptomatic [12]. Wexler et al. also found that
patients with symptomatic co-morbidities such as micro-
vascular complications and heart failure had a substantially
reduced QoL, while those without symptoms showed no
reduction [10]. These findings are also consistent with our
observation that peripheral neuropathy had a higher im-
pact on HRQoL than coronary artery disease and even
heart failure. It was surprising however for us to find that
heart failure did not reduce quality of life in our multivari-
able model while it did in the univariable analyses, because
it is in contrast to previous reports [10]. This might have
been due to multiple adjustments in the multivariable
model, which reduced the impact of heart failure.
We were not able to show a direct impact of physical
activity on HRQoL, which was elegantly demonstrate by
Daniele et al. [31], who found an improved HRQoL in
physically active patients with diabetes. This might pro-
vide, beyond improvements of metabolic control and
body weight, an opportunity to improve HRQoL.
Conclusions
The present study suggests, that co-morbidity but not
average glycaemic control reduces health related quality
of life in type 2 diabetes mellitus.Competing interests
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